XKRX
095700
Market cap98mUSD
Oct 08, Last price
2,905.00KRW
1D
-3.65%
1Q
20.29%
Jan 2017
-93.27%
IPO
-83.45%
Name
Genexine Inc
Chart & performance
P/E
—
P/S
28.89
EPS
—
Div yield, %
—
Shrs. gr., 5y
6.01%
Rev. gr., 5y
-24.42%
Revenues
4.57b
+55.96%
Net income
-27.01b
L-57.60%
CFO
-29.58b
L+1,694.72%
Dividend
Mar 15, 20220.3964 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Genexine, Inc. is a South Korean clinical-stage biotechnology firm dedicated to advancing and commercializing immunotherapeutics and extended-duration biologics. The company leverages two key proprietary technologies: the hyFc platform, engineered for discovering diverse agonistic protein therapeutics, and an Immune Enhancing Technology, which focuses on therapeutic DNA vaccines. Its extensive pipeline features several drug candidates: GX-H9, currently in Phase II trials for treating growth hormone deficiency in both adults and children; GX-E2, also in Phase II, addressing induced anemia; GX-G3, in Phase II for neutropenia; and GX-G6, undergoing Phase I studies for diabetes. Additionally, GX-188E is in Phase II clinical trials, being evaluated in combination with KEYTRUDA for cervical cancer treatment. Genexine has also forged a co-development alliance with Binex Co. Ltd. to create a COVID-19 vaccine. Founded in 1999 as Genexine Co., Ltd., the company adopted its current name, Genexine, Inc., in March 2013 and is headquartered in Seongnam, South Korea.
Key people
Co-Chief Executive Officer, Chief Financial Officer, Director · since 2025
Jang Hui Lee
Managing Director
Seong Gi Baek
Internal Auditor
Min Gyu Huh
Assistant Managing Director
Hyeon Cheol Jeon
Internal Auditor
Gi Wan Kim
Assistant Managing Director
Gi Yong Kim
Assistant Managing Director
Jae Hyeon Choi
Co-Chief Executive Officer, Director · since 2025
Yeong Cheol Sung
Chairman of the Board · since 2021
Jeong Won Woo
President, Director · since 2023
Yeong Jin Kim
Other Non-Executive Director
Jin Geon Bae
Non-Executive Independent Director
Peter Laivins
Non-Executive Independent Director
Ui Cheol Shin
Non-Executive Independent Director
Ho Yeong Song
Non-Executive Independent Director · since 2025
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||